Innovative Leaders in Medical
Consolidation and Growth
Home | Contact Us
 
Home
Mission
Overview
Team
News
Contact
Home arrow News
 
Med Opportunity Partners, LLC makes strategic investment in Pfanstiehl, Inc.
April 1, 2013 - Med Opportunity Partners, LLC (“MEDOP”), a Greenwich CT-based private equity firm focused exclusively on the health care sector, announced today its acquisition of Ferro Pfanstiehl Laboratories, Inc., a global leader in cGMP carbohydrates and Active Pharmaceutical Ingredients (APIs), from Ferro Corporation. MEDOP, a strategic, operating-oriented investment firm, brings significant resources, pharmaceutical and biopharmaceutical relationships, and capital to fuel the Company’s growth.
Read more...
 
Reliable Biopharmaceutical Corporation hires David Feldker

St. Louis, Missouri - September 27, 2010 

Reliable Biopharmaceutical Corporation ("RBC") today announced that David Feldker will join RBC and become its CEO and President effective October 23, 2010, and join RBC's Board of Directors.  David was previously Vice President SAFC at Sigma-Aldrich Corp. with responsibility for the Active Pharmaceutical Ingredient ("API") contract development and manufacturing segment.

Read more...
 
October 22, 2007

"Med Opportunity Partners Leads Purchase Of St. Louis Based Active Pharmaceutical Ingredient Manufacturer Reliable Biopharmaceutical Corporation"

Greenwich, CT, October 22nd, 2007 - Med Opportunity Partners LLC (MEDOP), a Greenwich CT-based operating oriented private equity firm, today announced the acquisition of Reliable Biopharmaceutical Corporation (RBC).

Read more...
 
| © Med Opportunity Partners, LLC 2005 - 2011. All rights reserved. This is not a public solicitation. | design by beckercommunications |